Global Pharma Companies Seek R&D Efficiency Lessons from China's Clinical Trial Success
核心洞察
China has accelerated drug development timelines by 50-70% through parallelized workflows and dense CRO ecosystems, capturing 39% of global clinical research share in 2023.
Major pharmaceutical companies are increasingly licensing Chinese assets not just for promising drugs, but to learn operational efficiency strategies that could transform their R&D processes.
While the FDA requires 20% of testing in the U.S. for drug approval, the remaining 80% can be conducted globally, creating opportunities for regions like China, Australia, and South Korea to attract clinical trials.
Multinational pharmaceutical companies are increasingly turning to China not just for promising drug assets, but to learn operational strategies that could revolutionize their research and development efficiency. This shift comes as China has demonstrated remarkable success in accelerating drug development timelines and capturing a dominant share of global clinical research.
China's Clinical Trial Transformation
China has managed to speed the timeline from early discovery to investigational new drug application by 50 to 70%, according to a recent McKinsey report. The region achieved this through parallelized workflows, dense contract research organization ecosystems and "a culture of executional intensity," the consulting firm noted.
This efficiency has translated into market dominance. China grew its share of clinical research to 39% in 2023, beating the U.S. and European Union in terms of patient recruitment and development timelines, McKinsey reported.
"A really interesting aspect of China is we'll be able to test more programs in early development, so get that clinical proof of concept more efficiently to see what's working and what's not," Robert Plenge, chief research officer at Bristol Myers Squibb (搜索), told BioSpace.
Beyond Asset Acquisition: Learning Operational Excellence
The growing interest in Chinese partnerships extends beyond simple licensing deals. According to Fangning Zhang, McKinsey & Company's leader of the life sciences practice in Greater China, pharmaceutical companies are increasingly curious about China's R&D capabilities.
"Some of the recent deals, at least on paper, it is a licensing deal," Zhang explained. "But part of that thesis is actually because the licensor believes the speed and cost efficiency of these China innovators actually could help them [get] into clinical trials faster and potentially cheaper."
This represents a strategic evolution for multinational companies that are "starting to think about their long-term commitments in China," Zhang said. Rather than simply acquiring individual assets, companies are considering whether they can adopt Chinese operational approaches more broadly.
Regulatory Advantages Drive Global Strategy
China's regulatory environment offers significant advantages for early-stage research. The country is "wide open for investigator-initiated trials (IIT)," which are tests run by independent researchers instead of pharma companies, according to John Wu, managing director and partner in the health care group at consulting firm BCG.
For modalities like cell and gene therapy, radioligand and stem cell therapy, there's no investigational new drug (IND) application required for an IIT in China, unlike at the FDA. This allows compounds to move quickly into human testing as long as a researcher has interest and funding.
However, companies cannot escape FDA requirements entirely. The agency maintains strict rules that at least 20% of testing must be done in the U.S. for a drug to be approved. Several companies have learned this lesson through high-profile rejections, including Eli Lilly and Innovent (搜索)'s PD-1 (搜索) checkpoint inhibitor sintilimab and Roche's loss of approval for Columvi in diffuse large B cell lymphoma (搜索) due to insufficient American data.
Major Investment Commitments
AstraZeneca exemplifies the growing commitment to Chinese operations with its recent pledge to spend $15 billion boosting R&D operations in the country. The investment, particularly aimed at the company's cell therapy and radioligand work, will apply to every step in the development process, from drug design and clinical development through manufacturing.
This follows a pattern of increasing investment as biopharmas add R&D staff in China, particularly as collaborations with companies like Wuxi Biologics (搜索) become increasingly risky due to potential Congressional action such as the BIOSECURE Act.
Expanding Deal Activity
The partnership landscape is rapidly evolving. Chinese deals have surged from 8% of global licensing activity to 30% in approximately two years, Zhang reported. This growth reflects both the quality of Chinese assets and the operational advantages they offer.
A recent example is the asset-swap agreement between Massachusetts-based Crescent Biopharma and Sichuan Kelun-Biotech (搜索) announced in December. The companies are each bringing a drug to the partnership: Crescent a PD-1 (搜索)/VEGF (搜索) inhibitor called CR-001 while Kelun-Biotech brings an antibody-drug conjugate SKB105 (搜索).
"By leveraging China's abundant clinical resources and execution efficiency, we aim to expedite clinical development while rigorously maintaining the highest global standards," Kelun-Biotech (搜索) CEO Michael Ge said in a statement.
Global Competition for Clinical Trials
Other regions are also positioning themselves to capture clinical trial activity. Australia offers Phase I research studies without requiring an IND, allowing research in humans to begin without the lengthy regulatory approval process needed in the U.S. The Australian government has also implemented favorable tax credits for research, with Wu estimating "a 43 cents on the dollar tax incentive for every R&D dollar spent there."
South Korea is stepping up clinical research, particularly leveraging the country's experience with antibody-drug conjugates and cell and gene therapies. India is also emerging as a potential destination, with many Indians returning home with international experience to launch new companies.
The European Union, meanwhile, has launched a campaign to win back clinical research after its share fell from 22% in 2013 to 12% in 2023. Through The Biotech Act, the European Commission seeks to shorten authorization timeframes for multinational clinical trials from 75 days to 47 days for applications that do not require additional information.
Maintaining Scientific Rigor
Despite concerns about data reproducibility from different regions, industry leaders emphasize that rigorous controls must be applied regardless of geography. "If you have a really good data package from any of those geographies, you should be able to use that information to guide clinical design in other geographies," Plenge noted.
However, companies must still navigate the fundamental constraint that the U.S. remains the biggest market, requiring compliance with FDA requirements. "There's a limit to which you can conduct trials outside of the U.S.," Wu said. "You cannot just satisfy a trial requirement from the U.S., because that would be too expensive, too slow, too competitive."